NEWS & BLOG
Stay up to date with the latest news and updates from KCNQ2 Cure.
Expanded Access of Kv7.2 Channel Activators
Kv7.2 Channel Activators In many cases, KCNQ2-DEE is caused by reduced Kv7.2 potassium channel activity. Because of this, therapeutics that boost the activity of these channels are likely to be…
Praxis EMERALD Clinical Trial
KCNQ2 Cure hosted a webinar for the KCNQ2 community featuring a discussion with Praxis Precision Medicines. Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for disorders…
Promising Results from EMBOLD Study: What this Means for the KCNQ2 Community
KCNQ2 Cure Alliance attended the American Epilepsy Society (AES) meeting this week. One of the biggest pieces of news shared was positive results from a clinical trial testing a new…
KCNQ2-DEE Clinical Trial
Xenon Pharmaceuticals is currently developing XEN496, which is a proprietary pediatric formulation of the active ingredient ezogabine, for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE). Ezogabine was previously…